Q3 Earnings Roundup: Zoetis (NYSE:ZTS) And The Rest Of The Branded Pharmaceuticals Segment
2 of Wall Street’s Favorite Stocks with Solid Fundamentals and 1 Facing Challenges
/Zoetis%20Inc%20logo%20on%20phone-by%20viewimage%20via%20Shutterstock.jpg)
Zoetis is expected to announce its fiscal fourth-quarter earnings next month, and analysts project earnings in line with the year-ago quarter.
1 Profitable Stock with Solid Fundamentals and 2 We Brush Off
2 Safe-and-Steady Stocks with Competitive Advantages and 1 We Turn Down
Zoetis Inc . (NYSE:ZTS) will host a webcast and conference call at 8:30 a.m. (ET) on Thursday, February 12, 2026. Chief Executive Officer Kristin Peck and Executive Vice President...
Zoetis Inc. (NYSE:ZTS) will participate in the 44 th Annual J.P. Morgan Healthcare Conference on Monday, January 12, 2026. Kristin Peck, Chief Executive Officer, and Wetteny Joseph,...
Substantially All of Net Proceeds Expected to Be Used to Repurchase Approximately $1.6 Billion of Common Stock and for Capped Call Transactions
Substantially All Net Proceeds Expected to Be Used to Repurchase Common Stock and for Capped Call Transactions
The Board of Directors of Zoetis Inc . (NYSE:ZTS) has declared a dividend of $0.53 per share for the first quarter of 2026, an increase of 6% from the quarterly dividend rate paid in 2025....